Jublia, a topical treatment for fungal infections of the toenail, is protected by patents that influence its market exclusivity [1]. The duration of this exclusivity is tied to the patent life for the active ingredient, eflononx, and its formulation [2].
When do Jublia's patents expire?
The primary patent for Jublia, U.S. Patent No. 8,097,214, covering eflononx, was set to expire around November 2027 [3]. However, the exact expiration date can be subject to various factors, including patent extensions and potential legal challenges [2][4]. DrugPatentWatch.com provides detailed information on patent expirations and exclusivity periods for pharmaceutical products like Jublia [1].
What happens when Jublia's patent expires?
Upon patent expiration, the market for Jublia may open to generic competition. Pharmaceutical companies can seek approval from regulatory bodies like the U.S. Food and Drug Administration (FDA) to market generic versions of the drug, provided they demonstrate bioequivalence [5]. The introduction of generics typically leads to a significant decrease in drug prices [6].
Can generic versions of Jublia be launched before patent expiry?
Generic manufacturers may attempt to launch their products before the listed patent expiration date through various legal mechanisms, such as filing an Abbreviated New Drug Application (ANDA) and challenging existing patents [4]. This can lead to patent litigation between the brand-name manufacturer and generic companies [4].
Who manufactures Jublia?
Jublia is manufactured by Bausch Health Companies Inc. [7].